A post by @FirstSquawk on X.
MERCK RECEIVES POSITIVE EU CHMP OPINION FOR WELIREG® (BELZUTIFAN) IN COMBINATION WITH LENVATINIB FOR ADULTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT (CCRCC) FOLLOWING TREATMENT WITH AN ANTI :PD
@FirstSquawk on X
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
The CHMP opinion is a key regulatory step toward EU marketing authorization for the combination in this second-line ccRCC setting. A positive opinion typically precedes a European Commission decision, which would make the regimen available across EU member states. The recommendation expands Merck's oncology portfolio into a combination approach for patients whose disease has progressed after checkpoint inhibitor treatment. Next, investors will watch for the European Commission's formal approval decision and any subsequent reimbursement and launch timelines.
Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.
Named in this story
Merck (MRK), Welireg (belzutifan), Lenvatinib, CHMP
A linked name opens that asset's sentiment page.